Valuation : Pulmatrix, Inc.

Market Cap 5.37M 4.62M 4.34M 3.96M 7.44M 511M 7.5M 51.43M 20.01M 259M 20.16M 19.72M 858M P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 1.28M 1.1M 1.04M 945K 1.78M 122M 1.79M 12.27M 4.77M 61.8M 4.81M 4.7M 205M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.23%
Yield 2024 *
-
Yield 2025 -
1 day-2.65%
1 week-5.16%
Current month-15.52%
1 month-15.52%
3 months+5.76%
6 months-28.99%
Current year-34.08%
1 week 1.45
Extreme 1.45
1.6
1 month 1.43
Extreme 1.43
1.75
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
5.5
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
20.8
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 19/07/2024
Director TitleAgeSince
Director/Board Member 58 31/10/2019
Director/Board Member 57 22/06/2020
Director/Board Member 55 30/09/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/01/23 Free

Chairman

2,436 0.0669%
26/01/23 Free

Director

1,700 0.0467%
26/01/23 Free

Director

1,700 0.0467%
Change 5-day change 1-year change 3-year change Capi.($)
-2.65%-5.16%-69.12%-37.45% 5.37M
-1.66%-4.96%+49.84%+88.43% 68.13B
+0.96%+2.31%+45.96%+90.23% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
+2.77%-1.74%-16.16%+456.51% 26.6B
-0.46%-9.94%+0.98%-15.98% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
-0.14%+0.24%+29.05%-19.81% 19.69B
-1.49%-6.35%+0.78%+540.26% 15.16B
+0.35%+0.16%+46.96%+144.04% 13.54B
Average -1.07%-2.96%+37.17%+163.60% 27.61B
Weighted average by Cap. -0.55%-2.34%+45.55%+146.51%

Financials

2024 2025
Net sales 7.81M 6.72M 6.31M 5.76M 10.82M 743M 10.9M 74.78M 29.1M 377M 29.31M 28.67M 1.25B -
Net income -9.56M -8.23M -7.73M -7.05M -13.25M -910M -13.35M -91.57M -35.63M -461M -35.89M -35.11M -1.53B -5.16M -4.44M -4.17M -3.81M -7.16M -491M -7.21M -49.45M -19.24M -249M -19.38M -18.96M -825M
Net Debt -9.52M -8.2M -7.7M -7.03M -13.2M -906M -13.29M -91.21M -35.49M -459M -35.75M -34.97M -1.52B -4.09M -3.52M -3.3M -3.02M -5.67M -389M -5.71M -39.16M -15.24M -197M -15.35M -15.02M -653M
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
31/08/26 US$1.470 -2.65% 2,567
28/08/26 US$1.510 -0.66% 3,316
27/08/26 US$1.520 -0.33% 14,049
26/08/26 US$1.525 -4.69% 5,307
25/08/26 US$1.600 +3.23% 12,199
  1. Stock Market
  2. Stocks
  3. PULM Stock